PODD
DisruptorInsulet Corporation
$197.81
+0.44%
as of 13 Apr
Power Core
Insulet's moat is the compound effect of a disposable, tubeless form factor and pharmacy-channel distribution that together create behavioral lock-in and expand the addressable market beyond what tubed-pump incumbents can reach.
Direction of Movement
Structural Momentum Across Four Observable Vectors
ROC 200
-33.4%
Market data unavailable
Company Profile
Insulet Corporation is a medical device company that develops, manufactures, and sells innovative insulin delivery systems, primarily through its Omnipod product platform, for people with insulin-dependent diabetes worldwide. The Omnipod offers a tubeless, wearable Pod that provides up to three days of continuous insulin delivery without needles or tubing, simplifying diabetes management and eliminating multiple daily injections. Key products include the Omnipod 5 Automated Insulin Delivery system, which integrates with third-party continuous glucose monitors via Bluetooth for automated insulin adjustments, and the Omnipod DASH insulin management system controlled by a smartphone-like device. Insulet Corporation also adapts its Pod technology for the subcutaneous delivery of non-insulin drugs in other therapeutic areas through partnerships. Available in over 25 countries across North America, Europe, the Middle East, and Asia Pacific, the company focuses on enhancing patient freedom and reducing the daily burden of diabetes care. Founded in 2000 and headquartered in Acton, Massachusetts, Insulet Corporation leads in tubeless automated insulin delivery solutions.